Trial Profile
Three-week pilot, randomised, double blind study of pexacerfont in patients with substance use disorder (amphetamine or opioid dependence)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Oct 2017
Price :
$35
*
At a glance
- Drugs Pexacerfont (Primary)
- Indications Substance withdrawal syndrome
- Focus Pharmacodynamics; Therapeutic Use
- 31 Oct 2017 New trial record
- 23 Oct 2017 Primary endpoint of changes in the Visual Analog Scale (VAS) score for craving has been met, according to results published in the International Clinical Psychopharmacology.
- 23 Oct 2017 Results published in the International Clinical Psychopharmacology